氟尿嘧啶、亚叶酸钙和奥沙利铂联合贝伐单抗治疗转移性结肠癌疗效观察

5-Fluorouracil,leucovorin,and oxaliplatin plus bevacizumab in the treatment of 32 metastatic colorectal cancer patients

目的评估氟尿嘧啶、亚叶酸钙和奥沙利铂（FOLFOX）方案联合贝伐单抗（Bevacizumab）在转移性结肠癌（MCRC）治疗中的疗效和不良反应。方法回顾分析我院2004年5月到2007年6月间接受FOLFOX联合贝伐单抗一线解救方案的32例MCRC患者的疗效和不良反应数据。Kaplan-Meier法计算生存曲线。结果共有32例MCRC患者接受了FOLFOX联合贝伐单抗一线解救治疗,其中21例中途停用奥沙利铂。全组患者总体有效率为40%。生存分析估计中位TTP为9.8个月,中位OS为22.9个月。3级神经病变、中性粒细胞减少症和腹泻的发生率分别为15.6%、9.4%、9.4%。结论使用FOLFOX联合Bevacizumab一线解救治疗MCRC患者有效,不良反应可以耐受。

Objective To evaluate the efficiency and adverse effect of the addition of bevacizumab to 5 - fluorouracil, leuco- vorin and oxaliplatin （FOLFOX） in the treatment of metastatic colorectal cancer （MCRC）. Methods Thirty - two patients treated with first - line FOLFOX plus bevacizumab between May 2004 and June 2007 were reviewed. Toxicity and efficacy data were collected. Overall survival and TI＇P were calculated according to Kaplan - Meier method. Results Oxaliplatin treatment was interrupted prior to progression in 21 patients. The overall response rate was 40%. Median TTP and median OS were 9.8months and 22.9 months, respec- tively. Grade 3 neuropathy, neutropenia and diarrhea occurred in 15.6%, 9.4%, and 9.4% of patients, respectively. Conclusions First -line FOLFOX plus bevacizumab is welholerated and effective.